💊#FDA Approval Update | #Sotyktu (#deucravacitinib): a #TYK-targeting therapy for adults with active #PsA
➡️To manage #skin & #joint symptoms
✅Significant #ACR20 responses in Phase 3 POETYK PsA-1 and PsA-2 trials
#PsoriaticArthritis #Autoimmune #AutoimmuneDisease

Bristol Myers Squibb leans into direct-to-consumer with telehealth launch, drug price drop Bristol Myers Squibb is expanding D2C drug sales with the launch of a new telehealth platform and a steep cash-pay discount for its psoriasis treatment Sotyktu.. The rise of drugmakers' telehealth pla...

#Sotyktu will launch on a new online platform called BMS Patient Connect in January for $950 per month, a decrease of more than 80% on the list price of $6,828, per BMS." #drugPrices

www.emarketer.com/content/bris...

Sotyktu vs Otezla: How do they compare? Official answer: Sotyktu and Otezla are both oral prescription medicines used to treat moderate-to-severe plaque psoriasis, but they...

#Sotyktu and #Otezla are both oral options for reducing inflammation in moderate-to-severe plaque psoriasis, but they target different pathways in the body.
Sotyktu works by blocking a protein called TYK2 (tyrosine kinase 2) and Otezla targets an enzyme called PDE4.

Sotyktu vs Otezla: How do they compare? Official answer: Sotyktu and Otezla are both oral prescription medicines used to treat moderate-to-severe plaque psoriasis, but they...

📋 Psoriasis Treatment Deep Dive
Two oral options for moderate-to-severe plaque psoriasis work in distinct ways:
#Sotyktu → Blocks TYK2 protein
#Otezla → Targets PDE4 enzyme
Both aim to reduce inflammation, just through different pathways.